Biomedical subjects

C Ahlstrand

Publications and source records attributed to C Ahlstrand.

23 records · Page 2Linked to original sources

PubMed1981

Metabolic effects of bendroflumethiazide in patients with recurrent calcium oxalate stone disease.

Two groups of patients with urolithiasis were treated with 2.5 mg. (group A) and 5.0 mg. (group B) bendroflumethiazide daily. There were 14 men and 3 women in group A, and 14 men and 2 women in group B in whom metabolic effects were followed during 1 year of treatment. Serum calcium was significantly increased in group B after 1 month but later returned to the pretreatment level. A significant decrease in serum magnesium was recorded in group B after 6 and 10 months. No significant effect on serum calcium or magnesium was observed in group A. Serum potassium decreased in both groups but serum urate remained at the pre-treatment level. An increased alkalinity was noted in both groups. Urinary calcium was decreased significantly only in group B. Although significantly increased excretion of magnesium was observed after 1 and 6 months in group A this was not encountered in group B, and after 12 months urinary magnesium was at the pre-treatment level in both groups. Urinary excretion of oxalate, urate and citrate appeared to be unaffected by the treatment. The inhibition of calcium oxalate crystal growth and urine volume did not change. The calcium/magnesium quotient decreased in both groups as did the calcium times oxalate/ magnesium quotient. The main metabolic effect of bendroflumethiazide, with respect to its stone prophylactic property, appears to be a decrease in the calcium/magnesium quotient and a dose of 5 mg. per day probably is more satisfactory than a 2.5 mg. dose.

Adult↗

PubMed1981

Renal stone disease in a Swedish district during one year.

In a Swedish district served by only one hospital the annual incidence of urinary stone colic was estimated to 1.4 per 1000 inhabitants. Sixty-two per cent of the patients were treated entirely as out patients whereas 9% required some form of surgery during the study. Thirty-seven per cent of the patients were recurrent stone formers. No significant seasonal variation in stone incidence was noted. A definite reason for stone formation could be established in 6%, and among 56 patients with recurrent stone disease run through a biochemical investigation, abnormal findings were recorded in 70%.

Adolescent↗

PubMed1981

[14C]Oxalate absorption by normal persons, calcium oxalate stone formers, and patients with surgically disturbed intestinal function.

Intestinal absorption of oxalate can be judged from the urinary excretion of orally administered [14C]oxalate. Fifteen normal subjects, 21 patients with "idiopathic" calcium oxalate stone disease and a high oxalate excretion, four patients operated with ileocecal resection, and seven patients operated with jejunoileal bypass were so investigated. We saw no significant difference in the amount of isotope excreted by normal subjects and idiopathic stone formers; 13.6% (SD 5.9%) and 14.4% (SD 6.5%), respectively, of the administered dose was accounted for in the urine. The patients with resection or bypass showed a quite different pattern of isotope excretion, and 18.3% (SD 7.0%) and 36.8% (SD 14.0%), respectively, of the isotope was accounted for in the urine.

Calcium Oxalate↗

PubMed1980

Urine composition in patients with urolithiasis during treatment with magnesium oxide.

Fifteen patients with recurrent renal stone formation were treated with 400 mg magnesium oxide daily. Urine composition was analyzed before the start of treatment and after 6-12 months. The urinary excretion of magnesium before and during treatment was 321 +/- 120 (mean +/- SD) and 409 +/- 140 mmol per mol creatinine respectively, a difference that was not statistically significant. Urinary calcium increased from 473 +/- 186 to 662 +/- 213 mmol per mol creatinine (p less than 0.05). All patients who increased their excretion of magnesium also increased the urinary output of calcium and, as a result of this, the calcium/magnesium-quotients were unaffected by the treatment. No significant effect was observed on urine oxalate excretion. Serum concentrations of calcium, magnesium and urate all remained at the pre-treatment level. From the results obtained in this study, magnesium oxide in this dosage cannot be recommended for use in treatment of patients with urolithiasis.

Calcium↗

PubMedDate not supplied

Human bladder cancer associated antigens: evaluation of antigenicity in TCC tissues of different grades and in normal urothelium.

The expression of five antigens, associated with transitional cell carcinoma (TCC) of the urinary bladder on biopsies of tumors or normal urothelium, was studied by immunostaining with the corresponding monoclonal antibodies. Both tissue sections and single cell preparations were investigated with either indirect immunoperoxidase staining or immunofluorescence. All 5 antigens were expressed on the majority (70-90%) of sectioned tumor specimens from 44 TCC patients, and 4 of them were similarly expressed on single cell tumor preparations from 26 additional patients. However, in both types of preparation, the degree of expression of these antigens varied from scattered staining of less than 25% of the tumor cells to homogenous staining of all or almost all cells. This degree of expression varied individually for each of the antigens and was not related to the malignancy grade of the tumors. However, as most of the tumors were of grades II or III, no conclusions regarding the relationship of antigen expression to the aggressiveness of the tumors can be drawn. In any event, all tumors expressed at least one and mostly several of these antigens. Antigen expression on biopsies of normal bladder mucosa from TCC patients or on urothelial biopsies from patients with prostate hyperplasia was also observed on single cell specimens (34 patients) but not on sectioned material (9 patients). However, the frequency of positive specimens was much lower (4-20%). Moreover, the number of cells expressing one or, occasionally, several of the antigens in normal urothelium was small (usually less than 5%). Because of these marked differences in antigen expression between tumors and normal tissue, the results indicate that a combination of 3-5 of the antibodies used in this study may be suitable for diagnostic purposes.

Antibodies, Monoclonal↗